A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
Latest Information Update: 27 Jul 2020
At a glance
- Drugs Ganetespib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MESO-02
- 15 Jul 2020 Results of phase I part of this study published in the Clinical Cancer Research.
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.